Central and Eastern Europe OTC Drugs Industry Outlook to 2017
Expanding Access to Distribution Channels to Lead Sales Growth
January 2014
229
About the Report
About the Report
Pharmstandard is the largest company with a market share of ~%. The revenue from the sales of OTC drugs by the company was recorded as USD ~ million in 2012 as compared to USD ~ million in 2011.
- The market size of Central and Eastern Europe OTC Drugs Market in terms of revenue, 2006-2012
- Market Segmentation in the region by product categories and by geography, 2006-2012
- Market Share of Leading Players in overall OTC Drugs Market in Russia, Poland, Ukraine, Hungary
- Market Share of Leading Players in different segments of OTC drugs in Russia
- Revenues of Top 10 Pharmaceutical Companies in Romania by Sales Value of OTC Cold and Flu Drugs, 2012
- Trends and Developments in the Central and Eastern Europe OTC Drugs industry and by geographies
- Government Regulations in the Pharmaceutical Sector in each Geography (excluding Slovakia)
- Competitive Landscape of Major Players in OTC Drugs Market in Russia, Poland, Ukraine and the Czech Republic.
- Future Outlook and Projections of OTC Drugs market in each Geography in the region, 2013-2017
Products
Products
Cold and Cough, Vitamins and Minerals, Digestives, Analgesics, Skin Products and Others otc drugs, pharmacy chains, medications, non-prescription
Companies
Sanofi Aventis, Novartis, Bayer Hungaria, Teva Magyarorszag, EGIS, USP Zdrowie, Aflofarm, GSK Consumer healthcare, Pharmstandard
Table of Contents
Table of Contents
1. Central and Eastern Europe OTC Drugs Market Introduction
1.1. Central and Eastern Europe OTC Drugs Market Size by Revenue, 2006-2012
2. Central and Eastern Europe OTC Drugs Market Segmentation, 2006-2012
2.1. By Product Categories, 2006-2012
2.2. By Geography, 2006-2012
3. Trends and Developments in Central and Eastern Europe Market
Mergers and Acquisitions in OTC Market in Central and Eastern Europe
Liberalization of OTC Drugs Distribution in 2011 in CEE
Online Sales of Drugs Permitted in Slovakia
Rearrangement of the Wholesale Market of Pharmaceuticals in the Region
Online sales of Drugs allowed in Bulgaria
4. Central and Eastern Europe OTC Drugs Market Future Outlook and Projections, 2013-2017
4.1. Central and Eastern Europe OTC Drugs Market Future Projections, 2013-2017
4.1.1. By Geography, 2013-2017
4.1.2. Cause and Effect Relationship Between Industry Factors and Central and Eastern Europe OTC Drugs Market Prospects
5. Russia OTC Drugs Market Introduction
5.1. Russia OTC Drugs Market Size, 2006-2012
5.1.1. By Revenue, 2006-2012
5.1.2. By Volume, 2008-2012
5.2. Russia OTC Drugs Market Segmentation, 2006-2012
5.2.1. By Cold and Cough, Analgesics, Digestives, Skin Products, Vitamins and Minerals and Others, 2006-2012
5.2.2. By Cities, 2012
5.3. Trends and Developments in Russia OTC Drugs Market
Approval of Selling of OTC Drugs in retail stores by Ministry of Healthcare
Appointment of New Government: Spurring Developments in Health Sector in Russia
Increasing Focus on Bio-Additives and Functional Nutrition
5.4. Government Regulations in Russia OTC Drugs Industry
Ban on Over the Counter Sales of Medical Drugs
Major Regulatory Changes in Russian Pharmaceutical Market in 2012
5.5. Market Share of Major Players in Russia OTC Drugs Market, 1H2013
5.5.1. By Anti Cold and Flu Drugs, 2012
5.5.2. By Non- Narcotic Analgesics and Antipyretic Drugs, 2012
5.5.3. By Expectorants & Antitussives (Cough Medications), 2012
5.5.4. By Multivitamins with Minerals, 2012
5.5.5. By Systematic Agents for Fungal Infections, 2012
5.6. Competitive Landscape of Major Players in RussiaOTC Drugs Market
5.7. Russia OTC Drugs Market Future Outlook andProjections, 2013-2017
5.8. Macro Economic Factors of Russia OTC Drugs Market: Historical and Projected
5.8.1. Population, 2006-2017
5.8.2. Public and Private Health Expenditure, 2006-2017
5.8.3. Consumer Price Index on Medicines, 2010-2012
6. Poland OTC Drugs Market Introduction
6.1. Poland OTC Drugs Market Size, 2006-2012
6.2. Poland OTC Drugs Market Segmentation, 2006-2012
6.2.1. By Products, 2006-2012
6.2.2. By Pharmacy and Non-Pharmacy Distribution Channel, 2011
6.3. Trends and Developments in Poland OTC Drugs Market
Rising Advertisement Expenditure by Pharmaceutical Companies
Plans to Launch New Products by Dietary Supplements Manufacturers
6.4. Government Regulations in Poland Pharmaceutical Market
General Overview
Reimbursement Act, 2012
6.5. Market Share of Major Players in Poland OTC Drugs Market, 2012
6.6. Competitive Landscape of Major Players in Poland OTC Drugs Market
6.7. Poland OTC Drugs Market Future Outlook and Projections, 2013-2017
6.8. Macro Economic Factors of Poland OTC Drugs Market: Historical and Projected
6.8.1. Population, 2006-2017
6.8.2. Health Expenditure Per Capita, 2006-2017
6.8.3. Consumer Price Index on Health, 2006-2012
6.8.4. Number of Pharmacies in Poland, 2006-2017
7. Ukraine OTC Drugs Market Introduction
7.1. Ukraine OTC Drugs Market Size, 2006-2012
7.2. Ukraine OTC Drugs Market Segmentation, 2006-2012
7.2.1. By Products, 2006-2012
7.3. Trends and Developments in Ukraine OTC Drugs Market
First Reading in Parliament on Act on Ban of Advertisement of OTC Medications in 2011
Act on Ban of Advertisements of OTC Medications Passed in 2012
Rapidly Changing Lifestyles Spurring OTC Drugs Sales
7.4. Government Regulations in Ukraine OTC Drugs Market
Permitting Drug Retail Only through Pharmacies
Rules Pertaining to Promotional Activities of Drugs
Recent Developments in Legal Regulation of Medicine and Healthcare in Ukraine
7.5. Market Share of Major Players in Ukraine OTC Drugs Market, 2012
7.6. Competitive Landscape of Major Players in Ukraine OTC Drugs Market
7.7. Ukraine OTC Drugs Market Future Outlook and Projections, 2013-2017
7.8. Macro Economic Factors of Ukraine OTC Drugs Market: historical and Projected
7.8.1. Population, 2006-2017
7.8.2. Health Expenditure of Households, 2006-2017
7.8.3. Consumer Price Index on Health, 2006-2012
8. The Czech Republic OTC Drugs Market Introduction
8.1. The Czech Republic OTC Drugs Market Size, 2006-2012
8.2. The Czech Republic OTC Drugs Market Segmentation, 2006-2012
8.2.1. By Products, 2006-2012
8.3. Trends and Developments in the Czech Republic OTC Drugs Market
Enactment of Reforms to Encourage Patients to Take greater Responsibility for Medical Treatment
Policies Geared Towards Reducing Costs in Healthcare
Restricted Development in 2008 due to Imposition of Mandatory Fees on Doctor Visit’s
Surging Investments in the Pharmaceutical Sector
8.4. Government Regulations on the Czech Republic Pharmaceutical Industry
General Overview
Mandatory Registration on Drugs for Manufacturing and Marketing
General Provisions on Promotion of Medicinal Products in the Market
8.5. Competitive Landscape of Major Players in the Czech Republic OTC Drugs Market
8.6. The Czech Republic OTC Drugs Market Future Outlook and Projections, 2013-2017
8.7. Macro Economic Factors of the Czech Republic OTC Drugs Market
8.7.1. Population, 2006-2017
8.7.2. Health Expenditure of Households, 2006-2017
8.7.3. Number of Pharmacies in the Czech Republic, 2006-2012
8.7.4. GDP (FROM Production Side), 2006-2017
9. Romania OTC Drugs Market Introduction
9.1. Romania OTC Drugs Market Size by Revenue and Volume, 2006-2012
9.2. Romania OTC Drugs Market Segmentation, 2006-2012
9.2.1. By Products, 2006-2012
9.3. Implication of Claw Back System in RomaniaPharmaceutical Industry
9.4. Trends and Developments in Romania OTC Drugs Market
Introduction of Clawback System Resulting in Rise in OTC Drugs Sales
Trends in Production of Pharmaceutical Drugs
9.5. Government Regulations in Romania Pharmaceutical Industry
Regulatory Framework: A General Overview
Pricing and Reimbursement Methodology
Pharmacy Law
9.6. Revenues of Top 10 Pharmaceutical Companies in Romania by Sales Value of OTC Cold and Flu Drugs, 2012
9.7. Romania OTC Drugs Market Future Outlook and Projections, 2013-2017
9.8. Macro Economic Factors of Romania OTC Drugs Market: Historical and Projected
9.8.1. Population, 2006-2017
9.8.2. Health Expenditure of Households, 2006-2017
9.8.3. Number of Pharmacies and Pharmaceutical Points in Romania, 2006-2017
10. Snapshot of Countries in OTC Drugs Market in Central and Eastern Europe
10.1. Hungary
10.1.1. Hungary OTC Drugs Market Size and Segmentation, 2006-2012
10.1.2. Distribution Channels of OTC Drugs in Hungary, 2012
10.1.2.1. Major OTC Products Sold in Pharmacies in Hungary, 2012
10.1.3. Recent Trends and Developments in Hungary OTC Drugs Market
Pharmacies in Hungary Permitted to Sell OTC Drugs Online
Reduced Spending by Pharmaceutical Companies in Hungary on Medical Journals in 2011
10.1.4. Hungary Pharmaceutical Regulatory Environment
Peculiar Taxes
Regulatory Framework Related to Opening of Pharmacies in Hungary
Regulations on Prices
Research and Development Based Tax Allowances
10.1.5. Market Share of Leading Players in Hungary OTC Drugs Market, 2012
10.1.6. Recent Developments of Companies in Hungary OTC Drugs Market
Government to co-found a company with vaccine manufacturer Omninvest
Gedeon Richter establishes new joint venture in China
Egis considering more than one acquisition
10.1.7. Hungary OTC Drugs Market Future Outlook and Projections, 2013-2017
10.2. Slovakia
10.2.1. Slovakia OTC Drugs Market Size and Segmentation, 2006-2012
10.2.2. Recent Trends and Developments in Slovakia OTC Drugs Market
Online Sales of OTC Drugs Permitted in Slovakia
Pricing structure
10.2.3. Slovakia OTC Drugs Future Outlook and Projections, 2013-2017
10.3. Bulgaria
10.3.1. Current Position, 2012
10.3.2. Bulgaria OTC Drugs Market Size and Segmentation, 2006-2012
10.3.3. Recent Trends and Developments in Bulgaria OTC Drugs Market
Legal Approval of Online Sales of OTC Drugs in Bulgaria
Bulgaria Pharma Market: 2012 Trends
10.3.4. Government Regulations in Bulgaria Pharmaceutical Market
Pricing System
10.3.5. Competitive Scenario of Major Players in Bulgaria OTC drugs Market
10.3.6. Bulgaria OTC Drugs Market Future Outlook and Projections, 2013-2017
11. Appendix
11.1. Market Definitions
11.2. Abbreviations
11.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
11.4. Disclaimer
List of Figure
Figure 1: Average Annual Per Capita Expenditure on Non-Prescriptions Drugs by Several Countries in Central and Eastern Europe in USD, 2010-2011
Figure 2: Central and Eastern Europe OTC Drugs Market Size by Revenue in USD Million, 2006-2012
Figure 3: Central and Eastern Europe OTC Drugs Market Segmentation by Cold and Cough, Digestives, Analgesics, Skin Products, Vitamins and Minerals and Others on the Basis of Contribution in Percentage(%), 2006-2012
Figure 4: Central and Eastern Europe OTC Drugs Market Average Annual Growth Rate by Geographies in Percentage (%), 2006-2012
Figure 5: Central and Eastern Europe OTC Drugs Market Segmentation by Geography on the Basis of Contribution in Percentage (%), 2006-2012
Figure 6: Central and Eastern Europe OTC Drugs Market Future Projections by Revenue in USD Million, 2013-2017
Figure 7: Russia OTC Drugs Market Size by Revenue in USD Million, 2006-2012
Figure 8: Russian OTC Drugs Market Size by Volume Sales in Million Packs, 2008-2012
Figure 9: Market Share of Major Players in Russian OTC Drugs Market in Percentage (%), 1H2013
Figure 10: Market Share of Anti Cold and Flu Drugs in Russia OTC Drugs Market by Name of the Drug and the Company in Percentage (%), 2012
Figure 11: Market Share of Non- Narcotic Analgesics and Antipyretic Drugs in Russia OTC Drugs Market by Name of the Drug and the Company in Percentage (%), 2012
Figure 12: Market Share of Expectorants & Antitussives in Russia OTC Drugs Market by Name of the Drug and the Company in Percentage (%), 2012
Figure 13: Market Share of Multivitamins with Minerals in Russia OTC Drugs Market by Name of the Drug and the Company in Percentage (%), 2012
Figure 14: Market Share of Systematic Agents for Fungal Infections in Russia OTC Drugs Market by Name of the Drug and the Company in Percentage (%), 2012
Figure 15: Russia OTC Drugs Market Future Projections on the Basis of Revenue in USD Million, 2013-2017
Figure 16: Population in Russia in Million, 2006-2017
Figure 17: Health Expenditure of Households in Russia in USD Million, 2006-2017
Figure 18: Poland OTC Drugs Market Size by Revenue in USD Million, 2006-2012
Figure 19: Poland OTC Drugs Market Segmentation by Cold and Cough, Vitamins and Minerals, Analgesics, Digestives, Skin Products and Others on the Basis of Contribution in Percentage(%), 2006-2012
Figure 20: Poland OTC Drugs Market Segmentation by Distribution through Pharmacy and Non-Pharmacy Chains on the Basis of Contribution in Percentage (%), 2011
Figure 21: Poland OTC Drugs Market Future Projections by Revenue in USD Million, 2013-2017
Figure 22: Population in Poland in Million, 2006-2017
Figure 23: Health Expenditure per Capita in Poland in USD, 2006-2017
Figure 24: Consumer Price Index on Health, 2006-2012
Figure 25: Number of Pharmacies in Poland, 2006-2017
Figure 26: Ukraine OTC Drugs Market Size by Revenue in USD Million, 2006-2012
Figure 27: Ukraine OTC Drugs Market Segmentation by Analgesics, Cold and Cough, Digestive Remedies, Skin Products, Vitamins and Minerals and Others on the Basis of Contribution in Percentage(%), 2006-2012
Figure 28: Market Share of Major Players in Ukraine OTC Drugs Market by Revenue in Percentage (%), 2009 and 2012
Figure 29: Ukraine OTC Drugs Market Future Projections by Revenue in USD Million, 2013-2017
Figure 30: Ukraine Population in Million, 2006-2017
Figure 31: Ukraine Average Annual Spending on Health Per Household in USD, 2006-2017
Figure 32: Consumer Price Index on Health in Ukraine, 2006-2012
Figure 33: The Czech Republic OTC Drugs Market Size by Revenue in USD Million, 2006-2012
Figure 34: The Czech Republic OTC Drugs Market Segmentation by Cold and Cough, Analgesics, Digestives, Vitamins and Minerals, Skin Products and Others on the Basis of Contribution in Percentage(%), 2006-2012
Figure 35: The Czech Republic OTC Drugs Market Future Projections by Revenue in USD Million, 2013-2017
Figure 36: The Czech Republic Population in Million, 2006-2017
Figure 37: Total Health Expenditure in the Czech Republic in USD Million, 2006-2017
Figure 38: Number of Pharmacies Registered with State Institute of Drug Control (SUKL) in the Czech Republic, 2006-2017
Figure 39: The Czech Republic GDP (from Production Side) in USD Million, 2006-2017
Figure 40: Romania OTC Drugs Market Size by Revenue in USD Million and Volume in Million Units, 2006-2012
Figure 41: Romania OTC Drugs Market Future Projections by Revenue in USD Million, 2013-2017
Figure 42: Romania Population in Million, 2006-2017
Figure 43: Consumer Expenditure on Health in Romania in USD, 2006-2017
Figure 44: Number of Pharmacies and Pharmaceutical Points in Romania, 2006-2017
Figure 45: Distribution Channels of OTC Drugs in Hungary on the Basis of Contribution in Percentage (%), 2012
Figure 46: Pharmacy Sales of OTC Products in Hungary by Revenue Contribution in Percentage (%), 2012
Figure 47: Market Share of Leading Players in Hungary OTC Drugs Market in Percentage (%), 2012
List of Table
Table 1: Central and Eastern Europe OTC Drugs Market Segmentation by Cold and Cough, Digestives, Analgesics, Skin Products, Vitamins and Minerals and Others on the Basis of Revenue in USD Million, 2006-2012
Table 2: Central and Eastern Europe OTC Drugs Market Segmentation by Geography on the Basis of Revenue in USD Million, 2006-2012
Table 3: Central and Eastern Europe OTC Drugs Market Future Projections by Geography on the Basis of Contribution in Percentage (%), 2013-2017
Table 4: Central and Eastern Europe OTC Drugs Market Future Projections by Geography on the Basis of Revenue in USD Million. 2013-2017
Table 5: Cause and Effect Relationship Analysis between Industry Factors and Expected Prospects of Central and Eastern Europe OTC Drugs Industry
Table 6: Russia OTC Drugs Market Segmentation by Cold and Cough, Digestives, Analgesics, Skin Products, Vitamins and Minerals and Others on the Basis of Revenue in USD Million, 2006-2012
Table 7: Number of Deaths in Russia due to Types of Diseases, 2007-2011
Table 8: Russia OTC Drug Sales by Regions on the Basis of Contribution in Percentage (%), 2012
Table 9: Top 10 OTC Drugs Sold by Pharmstandard in Russia by Volume in Million Packs and Sales Value in USD Million, 9M2013
Table 10: Difference between Narcotic and Non-Narcotic Analgesics Available in the Market
Table 11: Dosage of Nurofen for Children by Age, Quantity and Frequency of Dosage in a Day
Table 12: Competitive Landscape of Major Players in OTC Drugs Market in Russia
Table 13: Product Pipeline of Pharmstandard by Product, Group, Therapeutic Segment and Planned Launch, 2013
Table 14: Consumer Price Index on Medicines in Russia, 2010-2012
Table 15: Poland OTC Drugs Market Segmentation by Cold and Cough, Analgesics, Vitamins and Minerals, Digestives, Skin Products and Others on the Basis of Revenue in USD Million, 2006-2012
Table 16: Pharmacy Distribution Market in Poland by Sales Revenue in USD Million, 2006-2012
Table 17: Market Share of Leading Players in OTC Drugs Market in Poland, 2011-2012
Table 18: Competitive Landscape of Major Players in OTC Drugs Market in Poland
Table 19: Ukraine OTC Drugs Market Segmentation by Analgesics, Cold and Cough, Digestives, Skin Products, Vitamins and Minerals and Others on the Basis of Revenue in USD Million, 2006-2012
Table 20: Competitive Landscape of Major Players in Ukraine OTC Drugs Market
Table 21: Offer List of OTC Drugs in the Czech Republic by Name of the Supplement Drug and Approximate Price in CZK, 2013
Table 22: The Czech Republic OTC Drugs Market Segmentation by Cold and Cough, Analgesics, Vitamins and Minerals, Digestives, Skin Products and Others on the Basis of Revenue in USD Million, 2006-2012
Table 23: Competitive Landscape of Leading Players in OTC Drugs Market in the Czech Republic
Table 24: Inspections of the Czech Republic Pharmacies by Category, 2012
Table 25: Number of Pharmacies of Top 5 Pharmacy Chains in Romania, 2011
Table 26: Romania OTC Drugs Market Segmentation by Cold and Cough, Digestives, Vitamin and Minerals, Analgesics/ Antipyretics, Skin Products and Others on the Basis of Contribution in Percentage(%), 2006-2012
Table 27: Romania OTC Drugs Market Segmentation by Cold and Cough, Digestives, Vitamin and Minerals, Analgesics/ Antipyretics, Skin Products and Others on the Basis of Revenue in USD Million, 2006-2012
Table 28: Revenues of Top 10 Pharmaceutical Companies in Romania on OTC Cold and Flu Drugs Market, 2012
Table 29: Hungary OTC Drugs Market Size and Segmentation by Cold and Cough, Analgesics, Digestives, Skin Products, Vitamins and Minerals and Others on the Basis of Revenue in USD Million, 2006-2012
Table 30: Pharmacies Permitted to Sell OTC Drugs Online in Hungary, 2013
Table 31: Total Net Profit of Pharmacies in Hungary in USD Million, 2008-2011
Table 32: Number of Pharmacies in Hungary which made losses and Share of Pharmacies which made losses (%) as a proportion of the total number of pharmacies, 2008-2011
Table 33: Number of Advertisements and Amount Spent by Pharmaceutical Companies on Advertising in 88 medical Journals in Hungary in USD, 2010
Table 34: Number of Advertisements and Amount Spent by Pharmaceutical Companies on Advertising in 88 medical Journals in Hungary in USD, 2011
Table 35: Number of Pharmacies in Hungary by Change in Percentage (%) Base and Average Margin, 2006-2010
Table 36: Leading Players in Different OTC Product Categories in Hungary by Brands
Table 37: Hungary OTC Drugs Market Future Projections by Revenue in USD Million, 2013-2017
Table 38: Slovakia OTC Drugs Market Size and Segmentation by Cold and Cough, Vitamins and Minerals, Digestives, Analgesics, Skin Products and Others on the Basis of Revenue in USD Million, 2006-2012
Table 39: Consumption of Top 10 OTC Medications in Slovakia by Pharmaceutical Form, Manufacturer and Number of Packages Issued, 1Q2013
Table 40: Slovakia OTC Drugs Market Future Projections by Revenue in USD Million, 2013-2017
Table 41: Top 10 OTC Drugs in Bulgaria on the Basis of Units Sold in Million, 2008-2009
Table 42: Bulgaria OTC Drugs Market Size and Segmentation by Cold and Cough, Analgesics, Digestives, Skin Products, Vitamins and Minerals and Others on the Basis of Revenue in USD Million, 2006-2012
Table 43: Significant price reductions (BGN) after official investigation by the Pricing and Reimbursement Committee in Bulgaria, October 2012
Table 44: Price reductions (BGN) after official investigation by the Pricing and Reimbursement Committee in Bulgaria, 2012
Table 45: Bulgaria OTC Drugs Market Future Projections by Revenue in USD Million, 2013-2017
Table 46: Correlation Matrix of Poland OTC Drugs Industry
Table 47: Regression Coefficients Output of Poland OTC Drugs Market
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.